Vistagen reports preliminary positive open-label extension data for fasedienol
Vistagen said fasedienol nasal spray was well-tolerated in social anxiety disorder patients, with no new drug-related safety findings after as-needed use for up to 12 months. The company reported clinically relevant improvements over time on clinician- and patient-reported scales during the open-label extension portion of PALISADE-4.
Fasedienol nasal spray was well tolerated in patients with social anxiety disorder, with no new drug-related safety findings after as-needed use for up to 12 months. Clinically relevant improvement in social anxiety over time was observed on both clinician-administered and patient-reported scales over the study period.